Antiviral T cells safe and effective for treating debilitating complication common after stem cell transplants
(University of Texas M. D. Anderson Cancer Center) A Phase II trial at MD Anderson tound that BK virus (BKV)-specific T cells from healthy donors were safe and effective as an off-the-shelf therapy for BKV-associated hemorrhagic cystitis (BKV-HC), a painful complication common after allogeneic stem cell transplants for patients with leukemia or lymphoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 30, 2021 Category: Cancer & Oncology Source Type: news

Roche receives FDA clearance for BK virus quantitative test on cobas 6800/8800 Systems to support better care for transplant patients
Basel, 8 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) 510k clearance for the cobas ® BKV Test on the cobas® 6800 and 8800 Systems. The test was previously granted FDA Breakthrough Device designation demonstrating the improved treatment or diagnosis of life-threatening diseases or conditions for transplant patients. The test provides standardised, high-quality results that can he lp healthcare professionals better assess the risk of complications caused by the BK virus in transplant patients and identify effective treatment options. BK virus (BKV) is a member ...
Source: Roche Investor Update - September 8, 2020 Category: Pharmaceuticals Source Type: news

Roche receives FDA clearance for BK virus quantitative test on cobas 6800/8800 Systems to support better care for transplant patients
Basel, 8 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) 510k clearance for the cobas ® BKV Test on the cobas® 6800 and 8800 Systems. The test was previously granted FDA Breakthrough Device designation demonstrating the improved treatment or diagnosis of life-threatening diseases or conditions for transplant patients. The test provides standardised, high-quality results that can he lp healthcare professionals better assess the risk of complications caused by the BK virus in transplant patients and identify effective treatment options. BK virus (BKV) is a member ...
Source: Roche Media News - September 8, 2020 Category: Pharmaceuticals Source Type: news

A Novel Treatment Approach for PML A Novel Treatment Approach for PML
Progressive multifocal leukoencephalopathy, caused by the JC virus, has no known treatment. A new study offers a novel approach using T-cell infusions from the more treatable BK virus.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 19, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

A BK Virus Real-Time Quantitative AssayA BK Virus Real-Time Quantitative Assay
The authors present a new, highly sensitive, and reliable assay for measuring BK virus loads in plasma and identifying patients at risk of BKV-associated nephropathy. American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 22, 2016 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Use of antibiotic following kidney transplantation does not prevent virus infection
(The JAMA Network Journals) Among kidney transplant recipients, a 3-month course of the antibiotic levofloxacin following transplantation did not prevent the major complication known as BK virus from appearing in the urine. The intervention was associated with an increased risk of adverse events such as bacterial resistance, according to a study appearing in JAMA. The study is being released to coincide with its presentation at the American Society of Nephrology's annual Kidney Week meeting. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 15, 2014 Category: Global & Universal Source Type: news

Designer T Cells Fight Viruses After Transplants
WASHINGTON (AP) — Bone marrow transplants save thousands of lives but patients are vulnerable to severe viral infections in the months afterward, until their new immune system kicks in. Now scientists are developing protection for that risky period — injections of cells specially designed to fend off up to five different viruses at once. MoreNo Streams for You? What Supreme Court's Aereo Ruling Means NBC NewsJessica N. Turner: Moms, Put on That Swimsuit Huffington PostKnow a Debbie Downer? Stop Trying to Cheer Her Up NBC NewsViva! Pope Francis Flaunts Argentina Soccer Jersey NBC NewsUruguay eliminates Italy; Did Suarez...
Source: TIME: Top Science and Health Stories - June 25, 2014 Category: Science Authors: hannahgoldberg2014 Tags: Uncategorized medicine Research Science Source Type: news